Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling

a technology of c-fms and macrophage colony, which is applied in the direction of viruses, drug compositions, cardiovascular disorders, etc., can solve the problems of affecting the expression of c-fms, affecting and affecting the effect of mcsf, so as to inhibit the expression of mcsf. the effect of gene expression

Inactive Publication Date: 2007-07-24
RAJAVASHISTH TRIPATHI
View PDF45 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Inventions are described herein about methods called virus-mediated immunotherapies (VIM). These techniques involve delivering small amounts of DNA into living organisms like humans through injection or ingestion from outside sources. They use enzymes found within these agents to break down certain parts of their genome - specifically targeting messenger RNA sequences on those chromosomals – thereby causing damage to important organs involved in vital functions including blood flow regulation. V IM has been shown promising clinically due to its ability to silence various types of cancer stem cells while also being able to suppress tumors growth.

Problems solved by technology

The technical problem addressed in this patents relates to finding ways to prevent or reduce inflammations associated with cardiac diseases caused by excessive production of cytokines called interleukemia necrosis factors alpha (hereinafter referred to as IL-2) during development processes involving heart muscle metabolism. Experimental data showed that certain types of immunotheraphycy agents were able to block their effects through interactions between them within the same family but they did not work properly when applied externally because there was no way to release them outside the bloodstream quickly enough without being injected into the patient's circulate fluid like plasma. Therefore, methods are needed to efficiently introduce therapeutic drugs specifically towards MSCs involved in neurons.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
  • Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
  • Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling

Examples

Experimental program
Comparison scheme
Effect test

example 1

Cloning of c-fms Gene Sequences Expressing Antisense RNA or Soluble Protein

[0059]RT-PCR was performed to amplify c-fms gene DNA sequences corresponding to the ligand binding domain of the receptor using specific sets of primers on the DNA template produced from mouse or human macrophage mRNA. Human macrophages were grown from peripheral blood monocytes following standard protocols. Mouse macrophages were derived from bone marrow cells. Total cellular RNA was isolated by lysis of mouse or human macrophages in guanidinium isothiocyanate, phenol-chloroform extraction and ethanol precipitation. P Chomzynski, N Sacchi. “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156–159 (1987). To amplify the mouse and human c-fms gene sequence corresponding to the ligand binding domain (FIG. 1) two primers (cfms-1, SEQ ID NO. 5, nucleotides 75 to 93; and cfms-2, SEQ ID NO. 6, nucleotides 994 to 1008) were synthesized corresponding to

example 2

Construction and Purification of Recombinant Adenoviral Viral Vectors Expressing Either Antisense RNA or Soluble Protein

[0060]The choice of the Ad5 gene delivery system for c-fms gene was based on its ease of use, and many attractive features that allow the efficient transfer of genetic material as compared to other viral and non-viral (e.g., “naked” DNA or lipid coated DNA) gene delivery systems. Ad5 produces stable virions with high titers that are capable of transducing replicative and non-replicative cells. Ad5 has a wide host and tissue range and exhibits low pathogenicity in humans.

[0061]A 976 base pair EcoRI fragment of mouse c-fms cDNA was excised from pCRII plasmid and gel purified. For recombinant adenoviral transfer vector construction, BgIII linkers were attached to the 976 base pair fragment comprising the protein coding region of c-fms gene. This fragment was then ligated to a BgIII linearized transfer vector pQBIAdCMV5-GFP (Quantum Biotechnology, Inc., Montreal, Quebec,

example 3

Adenovirus Mediated c-fms Gene Transduction in Cultured Human and Mouse Macrophages

[0064]Macrophages, derived from either from human peripheral blood monocytes or from mouse bone marrow, were transduced with adenoviral vectors expressing antisense c-fms RNA (Ad5CMVc-fmsAS) or soluble c-fms protein (Ad5CMVc-fmsSA) linked to green fluorescence protein (GFP) to allow sorting of positive transfectants. Transfection efficiency of the recombinant virus at different MOI was determined by direct visualization and flow cytometric analysis of GFP fluorescent activity. The repression of c-fms in Ad5CMVc-fmsAS transduced macrophages was assessed 2 to 3 days post transduction by flow cytometry using human or murine c-fms specific antibodies. Antisense c-fms RNA effectively inhibited the expression of c-fms protein as shown by immunoblot analysis in a dose and time dependent manner. Cultured macrophages showed reduced growth in response to both antisense c-fms RNA expression and with the expression

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.
Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner RAJAVASHISTH TRIPATHI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products